HeartFlow is the newest unicorn after a new $150 million financing round

The medical technology company HeartFlow is now valued at over $1 billion, the latest company to hit the category threshold for the most highly valued startups.

HeartFlow is expected to collect $150 million in a new fundraising round, according to a new regulatory filing in Delaware uncovered by PitchBook. At a price of about $25.33 per share, HeartFlow will have a valuation of $1.4 billion.

The company did not immediately respond to a request for comment. It last raised money at a $760 million valuation in May 2016, according to PitchBook.

HeartFlow, founded in 2010, sells a product to doctors to detect coronary artery disease.

Investors have included U.S. Venture Partners, GE Ventures and the venture fund of insurer Blue Cross Blue Shield. The new backers of this funding round are not immediately known.

This article originally appeared on Recode.net.

We have a request

Vox's journalism is free because we believe that everyone deserves to understand the world that they live in. That kind of knowledge helps create better citizens, neighbors, friends, parents, consumers and stewards of this planet. In short, understanding benefits everyone. You can join in on this mission by making a financial gift to Vox today. Reader support helps keep our work free, for everyone. Will you join us?

One-Time Monthly Annual

$95/year

$120/year

$250/year

$350/year

Other

$

Yes, I'll give $120/year

Yes, I'll give $120/year

We accept credit card, Apple Pay, and Google Pay. You can also contribute via